Question

Difficulty: HardGastroenterology and Hepatology

A 72-year-old woman is admitted to the intensive care unit with a temperature of 39.2°C (102.6°F), severe right upper quadrant abdominal pain, and new-onset confusion. Her blood pressure is 88/54 mmHg, and her heart rate is 112/min. Physical examination is notable for marked scleral icterus and right upper quadrant tenderness with guarding.

Initial laboratory studies reveal:
TestResult
Leukocyte count18,500/mm³
Total bilirubin6.8 mg/dL
Direct bilirubin5.2 mg/dL
Alkaline phosphatase510 U/L
Aspartate aminotransferase (AST)145 U/L
Alanine aminotransferase (ALT)160 U/L

A bedside ultrasound shows a dilated common bile duct of 14 mm and an obstructive echogenic stone. She receives aggressive intravenous fluid resuscitation and is empirically started on broad-spectrum coverage with intravenous piperacillin-tazobactam. An emergent endoscopic retrograde cholangiopancreatography (ERCP) is performed, which successfully extracts the stone and drains purulent bile.

On hospital day 3, the patient is hemodynamically stable, alert, and afebrile. She is tolerating an oral diet. Blood cultures obtained at admission return positive for a single organism. The susceptibility report is as follows:

Organism: *Klebsiella pneumoniae*
AmpicillinResistant
CeftriaxoneSusceptible
CiprofloxacinSusceptible
Piperacillin-tazobactamSusceptible

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. De-escalate antimicrobial therapy to intravenous ceftriaxoneAnswer
  2. B
    Continue the current regimen of intravenous piperacillin-tazobactam
  3. C
    Add intravenous metronidazole to provide comprehensive anaerobic coverage
  4. D
    Transition therapy to oral rifaximin for outpatient management
  5. E
    Discontinue all antimicrobial therapy immediately

Answer

De-escalate antimicrobial therapy to intravenous ceftriaxone
The correct approach for a patient who has achieved clinical stability and source control (via ERCP) for bacteremic cholangitis is to tailor antimicrobial therapy based on culture results. The patient was appropriately started on empiric broad-spectrum therapy (piperacillin-tazobactam) given her initial presentation with septic shock. However, once blood cultures yield a single pathogen (Klebsiella pneumoniae) that is susceptible to narrower-spectrum agents like ceftriaxone, standard antimicrobial stewardship dictates de-escalation. Continuing broad-spectrum anti-pseudomonal and anaerobic coverage is unnecessary, increases the risk of adverse effects, and promotes antimicrobial resistance. Intravenous ceftriaxone is the ideal targeted agent to complete her 4-7 day treatment course.

Step-by-Step Solution

1
Identify the primary diagnosis and initial severity based on the clinical presentation.
The patient presented with acute ascending cholangitis complicated by septic shock (Reynolds pentad), necessitating immediate source control (ERCP) and broad-spectrum antibiotics (piperacillin-tazobactam).
Establishing the severity dictates the initial aggressive management strategy.
2
Evaluate the patient's current clinical status and the results of the interventions.
The patient is now hemodynamically stable and afebrile on hospital day 3, indicating successful source control and clinical response.
Clinical stability is a prerequisite for safely altering or de-escalating antimicrobial therapy.
3
Interpret the blood culture susceptibility data.
The infection is monomicrobial (Klebsiella pneumoniae) and is susceptible to ceftriaxone, ciprofloxacin, and piperacillin-tazobactam, but resistant to ampicillin.
Culture data guides the transition from empiric to targeted therapy.
4
Apply principles of antimicrobial stewardship to determine the next best step.
De-escalation from the broad-spectrum piperacillin-tazobactam to the narrower-spectrum ceftriaxone is indicated to complete the treatment course.
De-escalation minimizes the risk of multidrug-resistant organism emergence, collateral damage to the microbiome, and drug toxicity.

Key Concept

Antimicrobial Stewardship in Biliary Infections
Rate this question